Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results

Zolotova S.V.

Burdenko Neurosurgical Center

Anoshkin K.I.

Bochkov Medical Genetic Scientific Center

Absalyamova O.V.

Burdenko Neurosurgical Center

Makashova E.S.

Burdenko Neurosurgical Center;
Sechenov First Moscow State Medical University

Belyashova A.S.

Burdenko Neurosurgical Center

Telysheva E.N.

Burdenko Neurosurgical Center

ORCID: 0000-0002-0370-8667

Golanov A.V.

Burdenko Neurosurgical Center

Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results

Authors:

Zolotova S.V., Anoshkin K.I., Absalyamova O.V., Makashova E.S., Belyashova A.S., Telysheva E.N., Golanov A.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(3): 33‑40

DOI: 10.17116/neiro20228603133

Downloaded: 81

To cite this article:

Zolotova SV, Anoshkin KI, Absalyamova OV, Makashova ES, Belyashova AS, Telysheva EN, Golanov AV. Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results. Burdenko's Journal of Neurosurgery. 2022;86(3):33‑40. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20228603133

Close metadata

OBJECTIVE

To evaluate the incidence of TERT gene promoter mutations in adults with primary GB and to analyze the effect of TERT mutations on relapse-free and overall survival, as well as interaction of these mutations with MGMT gene methylation and IDH1/2 mutations.

MATERIAL AND METHODS

The study included 56 patients (26 women and 30 men) with histologically verified GB in which genetic and molecular investigations were performed. There were patients with life duration >3 years (n=15) and people with an extremely unfavorable course of disease (14 ones with primary multiple GB, 8 patients with GB metastases including extraaxial and 8 patients with life duration <8 months). TERT gene sequencingwas performed in all the cases, IDH1/2 status was known for 41 patients, MGMT status — for 23 patients.

RESULTS

Overall survival significantly differed between patients with and without TERT mutation (56 vs 17 months, p>0.05). TERT gene promoter mutation increased the effect of IDH1/2 mutations on overall and relapse-free survival (p=0.011). No TERT and IDH1/2 gene mutations worsened prognosis. There were no significant differences between TERT status and development of primary multiple GBs, as well as extra- and intracranial metastases.

CONCLUSION

Thus, the combined status of IDH1/2 and TERT mutations was a factor of better prognosis and can be proposed in clinical practice.

Keywords:

glioblastoma

IDH1/2

TERT

MGMT

Authors:

Zolotova S.V.

Burdenko Neurosurgical Center

Anoshkin K.I.

Bochkov Medical Genetic Scientific Center

Absalyamova O.V.

Burdenko Neurosurgical Center

Makashova E.S.

Burdenko Neurosurgical Center;
Sechenov First Moscow State Medical University

Belyashova A.S.

Burdenko Neurosurgical Center

Telysheva E.N.

Burdenko Neurosurgical Center

ORCID: 0000-0002-0370-8667

Golanov A.V.

Burdenko Neurosurgical Center

Received:

10.12.2021

Accepted:

25.03.2022

List of references:

Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro-Oncology. 2020;22(12 Suppl 2):1-96. https://doi.org/10.1093/neuonc/noaa200
Winograd E, Germano I, Wen P, Olson JJ, Ormond DR. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma. Journal of Neuro-Oncology. 2021;1-57. Online ahead of print. https://doi.org/10.1007/s11060-021-03876-7
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih I-M, Theodorescu D, Torbenson MS, Velculescu VE, Wang T-L, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(15):6021-6026. https://doi.org/10.1073/pnas.1303607110
Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nature Reviews. Genetics. 2019;20(5):299-309. https://doi.org/10.1038/s41576-019-0099-1
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349-352. https://doi.org/10.1126/science.279.5349.349
Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172-6183. https://doi.org/10.1038/s41388-019-0872-9
Im E, Yoon JB, Lee HW, Chung KC. Human telomerase reverse transcriptase (hTERT) positively regulates 26S proteasome activity. Journal of Cellular Physiology. 2017;232(8):2083-2093. https://doi.org/10.1002/jcp.25607
You H, Wu Y, Chang K, Shi X, Chen XD, Yan W, Li R. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds. CNS Neuroscience and Therapeutics. 2017;23(10):790-797. https://doi.org/10.1111/cns.12724
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-959. https://doi.org/10.1126/science.1229259
Reitman ZJ, Pirozzi CJ, Yan H.Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathologica. 2013;126(6):789-792. https://doi.org/10.1007/s00401-013-1207-5
Kikuchi Z, Shibahara I, Yamaki T, Yoshioka E, Shofuda T, Ohe R, Matsuda KI, Saito R, Kanamori M, Kanemura Y, Kumabe T, Tominaga T, Sonoda Y. TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neuro-Oncology Advances. 2020;2(1):vdaa114. https://doi.org/10.1093/noajnl/vdaa114
Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica. 2017;133(6): 1001-1006. https://doi.org/10.1007/s00401-017-1690-1
Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica. 2013;126(6):931-937. https://doi.org/10.1007/s00401-013-1163-0
Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200-1206. https://doi.org/10.1212/WNL.0000000000000814
Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications. 2016;4(1):79. https://doi.org/10.1186/s40478-016-0351-2
Mosrati MA, Malmström A, Lysiak M, Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus M, Stenmark-Askmalm M, Söderkvist P. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget. 2015;6(18):16663-16673. https://doi.org/10.18632/oncotarget.4389
Wang F, Fu P, Pang Y, Liu C, Shao Z, Zhu J, Li J, Wang T, Zhang X, Liu J. TERT rs2736100T/G polymorphism upregulates interleukin 6 expression in non-small cell lung cancer especially in adenocarcinoma. Tumour Biology. 2014;35(5):4667-4672. https://doi.org/10.1007/s13277-014-1611-z
Coward JI, Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine and Growth Factor Reviews. 2012;23(6):333-342. https://doi.org/10.1016/j.cytogfr.2012.08.005
Vuong HG, Nguyen TQ, Ngo TNM, Nguyen HC, Fung KM, Dunn IF. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: A meta-analysis. BMC Cancer. 2020;20(1):897. https://doi.org/10.1186/s12885-020-07364-5
Negrini S, De Palma R, Filaci G. Anti-cancer Immunotherapies Targeting Telomerase. Cancers (Basel). 2020;12(8):2260. https://doi.org/10.3390/cancers12082260
Mizukoshi E, Kaneko S. Telomerase-Targeted Cancer Immunotherapy. International Journal of Molecular Sciences. 2019;20(8):1823. https://doi.org/10.3390/ijms20081823
Lavanya C, Venkataswamy MM, Sibin MK, Srinivas Bharath MM, Chetan GK. Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells. Cytotechnology. 2018;70(4):1143-1154. https://doi.org/10.1007/s10616-018-0205-9

Close metadata